Reversible features of cervical cancer in human immunodeficiency virus infection

Impaired access, impaired surveillance, impaired immunity, impaired outcomes

Authors

  • Richard F. Little MPH, MD,

    Corresponding author
    1. Clinical Investigations Branch, Cancer Therapy Evaluation Program, Division of Cancer Therapy and Diagnosis, National Cancer Institute, Bethesda, Maryland
    • Clinical Investigations Branch, National Cancer Institute, EPN 7025, MSC 7436, Bethesda, MD 20892
    Search for more papers by this author
    • Fax: (301) 402-0557

  • Andrea M. Denicoff RN,

    1. Clinical Investigations Branch, Cancer Therapy Evaluation Program, Division of Cancer Therapy and Diagnosis, National Cancer Institute, Bethesda, Maryland
    Search for more papers by this author
  • Edward L. Trimble MD

    1. Clinical Investigations Branch, Cancer Therapy Evaluation Program, Division of Cancer Therapy and Diagnosis, National Cancer Institute, Bethesda, Maryland
    Search for more papers by this author

  • See referenced original article on pages 2683–9, this issue.

Abstract

Human immunodeficiency virus (HIV)-infected women with cervical cancer appear to have a greater degree of immunosuppression compared with HIV-infected women without cervical cancer. In addition, important issues relevant to health disparities appear to be associated with the risk of cervical cancer.

Ancillary